Ani Pharmaceuticals Stock Short Ratio

ANIP Stock

USD 64.87 0.65 1.01%

ANI Pharmaceuticals fundamentals help investors to digest information that contributes to ANI Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of ANI Stock. The fundamental analysis module provides a way to measure ANI Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ANI Pharmaceuticals stock.

Other Current Liab Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

ANI Pharmaceuticals Company Short Ratio Analysis

ANI Pharmaceuticals' Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.

Short Ratio

Short Interest

Average Trading Volume

More About Short Ratio | All Equity Analysis

Current ANI Pharmaceuticals Short Ratio

11.31 X

Most of ANI Pharmaceuticals' fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ANI Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

ANI Short Ratio Driver Correlations

Understanding the fundamental principles of building solid financial models for ANI Pharmaceuticals is extremely important. It helps to project a fair market value of ANI Stock properly, considering its historical fundamentals such as Short Ratio. Since ANI Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ANI Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ANI Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Short Term Debt	Short Term Investments	Current Deferred Revenue	Net Receivables	Net Tangible Assets	Long Term Debt	Good Will	Long Term Debt Total	Long Term Investments	Treasury Stock	Intangible Assets	Property Plant Equipment	Capital Surpluse	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Accumulated Depreciation
Total Assets		0.96	0.7	0.0	0.97	0.99	0.96	-0.42	-0.22	0.17	0.69	0.98	0.18	0.97	0.94	0.62	0.75	-0.74	0.96	0.87	0.83	-0.74	0.85	0.75	0.82	-0.77
Total Stockholder Equity	0.96		0.69	0.07	0.93	0.91	0.97	-0.47	-0.17	0.17	0.68	0.95	0.21	0.89	0.86	0.69	0.57	-0.79	0.87	0.89	0.9	-0.76	0.81	0.8	0.85	-0.78
Net Debt	0.7	0.69		0.24	0.62	0.68	0.53	-0.47	-0.28	0.3	0.29	0.75	-0.38	0.62	0.55	0.59	0.34	-0.82	0.77	0.86	0.67	-0.78	0.47	0.37	0.55	-0.44
Retained Earnings	0.0	0.07	0.24		-0.15	-0.03	-0.05	-0.86	0.41	0.27	0.01	-0.04	-0.2	-0.05	-0.2	0.15	-0.18	-0.18	0.06	0.18	0.02	-0.06	-0.21	-0.24	-0.21	0.25
Accounts Payable	0.97	0.93	0.62	-0.15		0.96	0.96	-0.3	-0.36	0.25	0.64	0.98	0.27	0.94	0.96	0.57	0.74	-0.74	0.88	0.83	0.83	-0.73	0.88	0.83	0.87	-0.86
Total Liab	0.99	0.91	0.68	-0.03	0.96		0.93	-0.38	-0.24	0.17	0.68	0.97	0.17	0.99	0.96	0.56	0.83	-0.69	0.97	0.83	0.77	-0.71	0.84	0.7	0.77	-0.73
Total Current Assets	0.96	0.97	0.53	-0.05	0.96	0.93		-0.39	-0.19	0.14	0.74	0.94	0.37	0.92	0.91	0.61	0.67	-0.68	0.84	0.8	0.85	-0.7	0.85	0.83	0.85	-0.83
Common Stock	-0.42	-0.47	-0.47	-0.86	-0.3	-0.38	-0.39		-0.2	-0.32	-0.38	-0.4	-0.01	-0.37	-0.27	-0.43	-0.15	0.43	-0.42	-0.48	-0.42	0.36	-0.23	-0.21	-0.26	0.22
Short Term Debt	-0.22	-0.17	-0.28	0.41	-0.36	-0.24	-0.19	-0.2		-0.33	0.11	-0.33	0.1	-0.24	-0.33	-0.22	-0.18	0.33	-0.19	-0.28	-0.25	0.61	-0.34	-0.48	-0.4	0.34
Short Term Investments	0.17	0.17	0.3	0.27	0.25	0.17	0.14	-0.32	-0.33		-0.17	0.26	0.03	0.15	0.18	-0.02	0.06	-0.42	0.14	0.35	0.28	-0.27	0.24	0.23	0.28	-0.2
Current Deferred Revenue	0.69	0.68	0.29	0.01	0.64	0.68	0.74	-0.38	0.11	-0.17		0.65	0.31	0.7	0.66	0.39	0.56	-0.18	0.62	0.34	0.56	-0.37	0.59	0.6	0.55	-0.74
Net Receivables	0.98	0.95	0.75	-0.04	0.98	0.97	0.94	-0.4	-0.33	0.26	0.65		0.15	0.95	0.94	0.62	0.71	-0.79	0.93	0.89	0.85	-0.78	0.85	0.78	0.85	-0.82
Net Tangible Assets	0.18	0.21	-0.38	-0.2	0.27	0.17	0.37	-0.01	0.1	0.03	0.31	0.15		0.25	0.3	0.07	0.2	0.07	-0.02	-0.02	0.21	0.08	0.3	0.38	0.33	-0.35
Long Term Debt	0.97	0.89	0.62	-0.05	0.94	0.99	0.92	-0.37	-0.24	0.15	0.7	0.95	0.25		0.97	0.56	0.85	-0.62	0.95	0.78	0.75	-0.68	0.84	0.72	0.77	-0.72
Good Will	0.94	0.86	0.55	-0.2	0.96	0.96	0.91	-0.27	-0.33	0.18	0.66	0.94	0.3	0.97		0.47	0.85	-0.58	0.9	0.73	0.75	-0.62	0.89	0.77	0.84	-0.78
Long Term Debt Total	0.62	0.69	0.59	0.15	0.57	0.56	0.61	-0.43	-0.22	-0.02	0.39	0.62	0.07	0.56	0.47		0.3	-0.66	0.55	0.69	0.76	-0.74	0.58	0.63	0.6	-0.44
Long Term Investments	0.75	0.57	0.34	-0.18	0.74	0.83	0.67	-0.15	-0.18	0.06	0.56	0.71	0.2	0.85	0.85	0.3		-0.31	0.8	0.46	0.47	-0.35	0.78	0.51	0.53	-0.49
Treasury Stock	-0.74	-0.79	-0.82	-0.18	-0.74	-0.69	-0.68	0.43	0.33	-0.42	-0.18	-0.79	0.07	-0.62	-0.58	-0.66	-0.31		-0.69	-0.97	-0.76	0.81	-0.57	-0.53	-0.64	0.54
Intangible Assets	0.96	0.87	0.77	0.06	0.88	0.97	0.84	-0.42	-0.19	0.14	0.62	0.93	-0.02	0.95	0.9	0.55	0.8	-0.69		0.84	0.72	-0.69	0.76	0.59	0.69	-0.62
Property Plant Equipment	0.87	0.89	0.86	0.18	0.83	0.83	0.8	-0.48	-0.28	0.35	0.34	0.89	-0.02	0.78	0.73	0.69	0.46	-0.97	0.84		0.82	-0.83	0.67	0.6	0.72	-0.58
Capital Surpluse	0.83	0.9	0.67	0.02	0.83	0.77	0.85	-0.42	-0.25	0.28	0.56	0.85	0.21	0.75	0.75	0.76	0.47	-0.76	0.72	0.82		-0.75	0.87	0.86	0.93	-0.73
Short Long Term Debt	-0.74	-0.76	-0.78	-0.06	-0.73	-0.71	-0.7	0.36	0.61	-0.27	-0.37	-0.78	0.08	-0.68	-0.62	-0.74	-0.35	0.81	-0.69	-0.83	-0.75		-0.6	-0.69	-0.68	0.58
Net Invested Capital	0.85	0.81	0.47	-0.21	0.88	0.84	0.85	-0.23	-0.34	0.24	0.59	0.85	0.3	0.84	0.89	0.58	0.78	-0.57	0.76	0.67	0.87	-0.6		0.89	0.91	-0.74
Net Working Capital	0.75	0.8	0.37	-0.24	0.83	0.7	0.83	-0.21	-0.48	0.23	0.6	0.78	0.38	0.72	0.77	0.63	0.51	-0.53	0.59	0.6	0.86	-0.69	0.89		0.92	-0.81
Capital Stock	0.82	0.85	0.55	-0.21	0.87	0.77	0.85	-0.26	-0.4	0.28	0.55	0.85	0.33	0.77	0.84	0.6	0.53	-0.64	0.69	0.72	0.93	-0.68	0.91	0.92		-0.8
Accumulated Depreciation	-0.77	-0.78	-0.44	0.25	-0.86	-0.73	-0.83	0.22	0.34	-0.2	-0.74	-0.82	-0.35	-0.72	-0.78	-0.44	-0.49	0.54	-0.62	-0.58	-0.73	0.58	-0.74	-0.81	-0.8

Click cells to compare fundamentals

The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.

Competition

Predict ANI Pharmaceuticals

Based on the latest financial disclosure, ANI Pharmaceuticals has a Short Ratio of 11.31 times. This is 190.0% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The short ratio for all United States stocks is 182.75% lower than that of the firm.

ANI Short Ratio Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ANI Pharmaceuticals' direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ANI Pharmaceuticals could also be used in its relative valuation, which is a method of valuing ANI Pharmaceuticals by comparing valuation metrics of similar companies.

ANI Pharmaceuticals is currently under evaluation in short ratio category among its peers.

ANI Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ANI Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ANI Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

ANI Pharmaceuticals Institutional Holders

Institutional Holdings refers to the ownership stake in ANI Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ANI Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ANI Pharmaceuticals' value.

		Shares
Macquarie Group Ltd	2024-12-31	562.6 K
William Blair Investment Management, Llc	2024-12-31	485.3 K
Geode Capital Management, Llc	2024-12-31	429 K
Tang Capital Management Llc	2024-12-31	317.5 K
Assenagon Asset Management Sa	2024-12-31	311.6 K
Thompson, Siegel & Walmsley Llc	2024-12-31	283.9 K
Ameriprise Financial Inc	2024-12-31	271.8 K
Jpmorgan Chase & Co	2024-12-31	268.1 K
Aberdeen Group Plc	2024-12-31	238 K
Blackrock Inc	2024-12-31	2.7 M
Vanguard Group Inc	2024-12-31	1.3 M

ANI Fundamentals

	Return On Equity	-0.0418
	Return On Asset	0.0084
	Profit Margin	(0.03) %
	Operating Margin	0.01 %
	Current Valuation	1.9 B
	Shares Outstanding	21.76 M
	Shares Owned By Insiders	11.22 %
	Shares Owned By Institutions	97.41 %
	Number Of Shares Shorted	2.56 M
	Price To Earning	43.35 X
	Price To Book	3.47 X
	Price To Sales	2.27 X
	Revenue	614.38 M
	Gross Profit	364.17 M
	EBITDA	63.12 M
	Net Income	(18.52 M)
	Cash And Equivalents	63.38 M
	Cash Per Share	3.89 X
	Total Debt	314.98 M
	Debt To Equity	0.85 %
	Current Ratio	3.35 X
	Book Value Per Share	20.54 X
	Cash Flow From Operations	64.02 M
	Short Ratio	11.31 X
	Earnings Per Share	(1.04) X
	Price To Earnings To Growth	1.06 X
	Target Price	81.5
	Number Of Employees	897
	Beta	0.63
	Market Capitalization	1.4 B
	Total Asset	1.28 B
	Retained Earnings	(100.28 M)
	Working Capital	334 M
	Current Asset	192.58 M
	Current Liabilities	11.76 M
	Net Asset	1.28 B

About ANI Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze ANI Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ANI Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ANI Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Additional Tools for ANI Stock Analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC